Epidemiology

Internal medicine

Disease

Trophoblastic neoplasm

Gestational trophoblastic neoplasia

Biology

Obstetrics

Oncology

Stage (stratigraphy)

Paleontology

Human chorionic gonadotropin

Gestational trophoblastic disease

Chemotherapy

Molar pregnancy

Gynecology

Pregnancy

Gestation

Radiation therapy

Genetics

Hormone

Medicine

International Journal of Gynecology & Obstetrics

Gestational trophoblastic disease (GTD) arises from abnormal placenta and is composed of a spectrum of premalignant to malignant disorders. Changes in epidemiology of GTD have been noted in various countries. In addition to histology, molecular genetic studies can help in the diagnostic pathway. Earlier detection of molar pregnancy by ultrasound has resulted in changes in clinical presentation and decreased morbidity from uterine evacuation. Follow-up with human chorionic gonadotropin (hCG) is essential for early diagnosis of gestational trophoblastic neoplasia (GTN). The duration of hCG monitoring varies depending on histological type and regression rate. Low-risk GTN (FIGO Stages I-III: score <7) is treated with single-agent chemotherapy but may require additional agents; although scores 5-6 are associated with more drug resistance, overall survival approaches 100%. High-risk GTN (FIGO Stages II-III: score ≥7 and Stage IV) is treated with multiagent chemotherapy, with or without adjuvant surgery for excision of resistant foci of disease or radiotherapy for brain metastases, achieving a survival rate of approximately 90%. Gentle induction chemotherapy helps reduce early deaths in patients with extensive tumor burden, but late mortality still occurs from recurrent treatment-resistant tumors.

Diagnosis and management of gestational trophoblastic disease: 2021 update